|
gptkbp:instanceOf
|
gptkb:drug
alpha-1 adrenergic receptor antagonist
|
|
gptkbp:approvalYear
|
2006
|
|
gptkbp:ATCCode
|
G04CA04
|
|
gptkbp:brand
|
gptkb:Rapaflo
|
|
gptkbp:CASNumber
|
160970-54-7
|
|
gptkbp:contraindication
|
severe renal impairment
severe hepatic impairment
|
|
gptkbp:drugInteraction
|
strong CYP3A4 inhibitors
P-glycoprotein inhibitors
|
|
gptkbp:eliminationHalfLife
|
13 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstApproval
|
gptkb:Japan
|
|
gptkbp:hasMolecularFormula
|
C25H32F3N3O4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Silodosin
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Kissei_Pharmaceutical
gptkb:Watson_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
selective alpha-1A adrenergic receptor blockade
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
Not recommended
|
|
gptkbp:proteinBinding
|
97%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:orthostatic_hypotension
dizziness
retrograde ejaculation
|
|
gptkbp:usedFor
|
gptkb:benign_prostatic_hyperplasia
|
|
gptkbp:bfsParent
|
gptkb:Recordati
|
|
gptkbp:bfsLayer
|
7
|